Clinical trials have been conducted or are currently underway using IL-15 as monotherapy or in combination with ipilimumab and nivolumab in patients with advanced solid tumors rendering IL-15 a promising anti-cancer immunotherapy (14–16). The gene discussed is IL15; the disease is cancer.